Network Silicon Valley Club的动态

As 2024 comes to a close, I can’t help but feel an overwhelming sense of gratitude and excitement for what we’ve accomplished at Alpenglow Biosciences this year—and the trailblazing road ahead. ?? Being part of a team pushing the boundaries of 3D spatial biology has been nothing short of inspiring. This year, we made huge strides toward transforming pathology as we know it, making diagnostics faster, more accurate, and more personalized. ?? Breaking Barriers in Innovation We achieved a game-changing $24M in funding—resources that empower us to reimagine what’s possible, supporting our work in 3D tissue imaging and accelerating diagnostics, harnessing AI to provide clinicians with tools for better decision-making. These investments are a vote of confidence in our Aurora? platform and its ability to make a real difference in patient outcomes. ?? ?? Shaping the Future of 3D Spatial Biology We didn’t just innovate; we shared our story and expertise with the world: At the 3D Spatial Summit, we brought together top minds in science to chart the future of this exciting field. Moments like these remind me of how powerful collaboration and knowledge-sharing can be. ?? ?? Earning Industry Recognition This year, Alpenglow Biosciences was honored as one of Genetic Engineering & Biotechnology News' Up and Coming Top Spatial Biology Companies of 2024. This recognition underscores our leadership in this rapidly growing field. ?? Looking to 2025 The best part? We’re just getting started. In 2025, we’ll continue to push the boundaries of what 3D spatial biology can achieve—delivering even greater innovation for patients, clinicians, and the research community. A huge thank you to everyone who’s been part of this journey: our team, partners, and supporters. Your belief in our mission inspires me every day. Here’s to another year of bold ideas, breakthroughs, and impact. Let’s make 2025 unforgettable! ?? #EndOfYearReflection #3DSpatialBiology #CancerDiagnostics #Innovation

?? Thrilled to share a sneak peek of my upcoming poster at Multi-Omics Brisbane 2024 with Alpenglow Biosciences. In this video preview, you can see our 3D imaging of neutrophils and lymphocytes in melanoma tissue, captured using our modified iDISCO+ protocol. The staining shows neutrophil elastase (NE, red), CD45 (green), and nuclei (ToPro3, blue). Credit: Alexandra Alvarsson, PhD I'll be presenting our latest work on automated classification and segmentation systems for 3D spatial biology analysis. We've developed innovative approaches that are transforming how we understand cellular interactions in complex tissue environments. ?? Presentation Details: Poster #119 Title: 3D Tissue Scale Automated Segmentation with Alpenglow 3Dai Spatial Analysis Suite Location: Multi-Omics Brisbane 2024 Would love to connect! Drop by the poster session to chat, or let's arrange a coffee! #SpatialBiology #BioTech #ResearchAndDevelopment #MultiOmics2024 #3DImaging #CellularAnalysis #MachineLearning

The PREVEDO project, in collaboration with the Università degli Studi di Salerno, is moving forward!! This 30-month initiative is advancing innovation by enhancing AI-driven predictions for treatment outcomes in cardiology. Funded by the Ministero delle Imprese e del Made in Italy , PREVEDO is part of the "Agreements for Innovation" program. Giuseppe Sgro Raffaele Maccioni Elvira Plenzich Roberto Tufano Francesca Aiello

?? New Article Alert! ?? Are you delving into the fascinating world of animal in vivo imaging? ?? Our latest article, "Animal In Vivo Imaging: how to Choose Between Bioluminescence or Fluorescence Imaging," is a must-read for researchers seeking to make informed decisions about their imaging techniques. https://lnkd.in/gvDNxF_n Dive deep into the advantages and considerations of bioluminescence vs. fluorescence imaging, and discover which method best suits your experimental needs. ?#anmimalinvivoimaging#

Have you heard of Dockstore.org? It's a product of the Ontario Institute for Cancer Research and the UC Santa Cruz Genomics Institute that tries to make it easier to share and use scientific workflows, which can be complicated and difficult to reproduce. There's a new release coming out today! Dockstore 1.16 highlights: ? AI-generated documentation for a workflow when none is provided ???? Improved search result UI ?? Automatic DOI generation (preview) ??? Discover existing DOIs generated for workflows ?? General usability improvements for finding and syncing to Dockstore Great job Denis, Stephen, Kathy, Charles and Nayeon and the PIs Benedict Paten and Lincoln Stein!! #bioinformatics #workflows #reproducibility #generative #science #nextflow #wdl #cwl

VentureLabs’ frequent speaker and expert in fundraising and market analysis, Geoffrey Hansen, attended the Consumer Electronics Show (CES) in Las Vegas to explore cutting-edge innovations. One standout company that also attended was MetaOptima Technology Inc., co-founded by Simon Fraser University Computing Science PhD grad Maryam Sadeghi. MetaOptima is revolutionizing skin cancer prevention and early diagnosis with its AI-driven solutions, showcasing the power of technology in healthcare. #CES2025 #SFUInnovates SFU Venture Connection / Chang Institute

?? Breaking Tech News! ?? Today, we’re witnessing a game-changer in the world of healthcare and organ transplantation—genetically engineered organs have now been successfully implanted into humans! This revolutionary breakthrough could potentially save millions of lives worldwide by addressing the critical shortage of donor organs. Using cutting-edge CRISPR-Cas9 technology, scientists have made it possible to modify animal organs for human use, marking a massive leap in medical science. ???? Get ready for a future where waiting lists for organs could be a thing of the past, thanks to this incredible innovation. ?? CRISPR’s Impact, Today (harvard.edu) #TechForGood #HealthcareInnovation #CRISPR #MedicalBreakthrough #RiseWithCode

Over nearly two decades, we've demonstrated that mission-driven entrepreneurship can revolutionize healthcare. By bridging engineering, biology, and genetics, our team has expanded from IVF to transformative diagnostics in prenatal care, oncology, and organ health. Our journey proves that constraints can be catalysts for innovation, and believing in scientific integrity is the ultimate competitive advantage. Hear more from our founders Matthew Rabinowitz and Jonathan Sheena, plus CEO Steve Chapman, and Naterans Chitra Kotwaliwale, Ph.D. and Sarah Elliott (Berridge) in this Crucible Moments podcast episode from Sequoia Capital. https://ow.ly/HASF50UbK1F

?? Curious about insights from your research using cutting-edge single-cell and spatial biology technologies? ?? You can deeply characterize cell populations and states with single-cell 10x Genomics #Chromium or discover complex tissue structures, neighborhoods, and cell-to-cell interactions, integrated with other spatial-omics, histology, and morphology through the in situ #Xenium 10x Genomics platform. Both technologies are part of a broad spectrum of services at Labena Slovenia’s Contact Research & Development Labs. ?? Dive into a short presentation of our daily lab routine and take your research to a whole new level with our dynamic team. #labenagroup #labenaslovenia #supportingscience #singlecelltranscriptomics #spatialtranscriptomics #10xspatialtranscriptomics #certifiedserviceprovider #development #labena #CRO #contactresearch #10xgenomics #10xgenomicsserviceprovider #10xgenomicsxenium #10xgenomicschromium #xenium #chomium #xeniumexplorer #insitu #geneexpression #cellranger #singlecellspatialtranscriptomics #geneexpressionprofiling #molecularprofiling #cellularheterogeneity #research

“The most rewarding part is the general knowledge that the work I'm doing with my colleagues is having an impact on patient care.” We recently had the chance to speak with Morghan Lucas (Co-Lead of Research & Development, MGZ - Medical Genetics Center) about the transformative potential of multi-omics, advances in sequencing technologies, and the importance of working across disciplines to drive innovation in diagnostics. With experience spanning genomics, epigenomics, and transcriptomics, Morghan is deeply committed to advancing diagnostic methods for diseases like cancer and muscular dystrophy. But how can multi-omics approaches improve patient care, and what does the future hold for technologies like liquid biopsies and real-time sequencing? Find out what Morghan had to say in her insightful interview on our website. And if you want to hear more from Morghan, you’re in luck – she’ll be speaking at The Festival of Genomics and Biodata next month in London! There’s no better place to immerse yourself in all things #genomics, #biodata and more, and don’t just take our word for it – scroll through to see why Morghan thinks you should attend. #FOG2025?